Medizinische Universität Graz - Research portal
Navigation/Search
- Researchers
- Institutions
- Projects
- Publications
- Partners
- Sponsors
- Equipment
- Knowhow
- Fields of Research
"Faces" of the day:
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Foris, V; Kovacs, G; Olschewski, H.
Update on pulmonary hypertension focusing on lung diseases
PNEUMOLOGE. 2021; 18(3): 195-206.
Doi: 10.1007/s10405-021-00392-3
Web of Science
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Foris Vasile
- Olschewski Horst
- Co-authors Med Uni Graz
- Kovacs Gabor
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Pulmonary hypertension (PH) is divided into five groups according to the current sixth World Symposium on Pulmonary Hypertension (WSPH), i.e. pulmonary arterial hypertension (PAH, group 1), PH due to left cardiac diseases (group 2), PH due to lung diseases and/or hypoxia (group 3), chronic thromboembolic PH (CTEPH, group 4) and PH with unclear or multifactorial causes (group 5). The diagnosis is based on the right heart catheter investigation, which requires a mean pulmonary arterial pressure > 20 mm Hg. The most important noninvasive diagnostic examination is echocardiography but electrocardiography, chest X-ray and the diffusing capacity of the lungs for carbon monoxide (DLCO) are also important. The treatment recommendations for PAH include five approved substance classes as single or combined treatment for PAH and inoperable CTEPH. For the group 3 PH a PAH treatment is not recommended apart from the subgroup with impending right ventricular heart failure.
- Find related publications in this database (Keywords)
- Hemodynamics
- Pulmonary arterial hypertension
- Right heart catheter
- Echocardiography
- Drug therapy
- combination